

Name of Journal: *World Journal of Clinical Cases*

Manuscript NO: 45205

Manuscript Type: CASE REPORT

Sustained complete response to erlotinib in squamous cell carcinoma of the head and neck: A case report

Mie Mie Thinn, Chung-Tzu Hsueh, Chung-Tsen Hsueh

Abstract

BACKGROUND

Squamous cell carcinoma of head and neck is the fifth most common cancer worldwide. Inhibition of epidermal growth factor receptor signaling has been shown to be a critical component of therapeutic option. Herein, we report a case

Match Overview

1	Internet 53 words crawled on 06-Dec-2018 emedicine.medscape.com	3%
2	Internet 35 words crawled on 24-Feb-2017 jamanetwork.com	2%
3	Internet 27 words crawled on 27-Jan-2010 annonc.oxfordjournals.org	1%
4	Internet 24 words crawled on 15-Jun-2018 www.jove.com	1%
5	Crossref 20 words Rancoule, Chloé, Alexis Vallard, Sophie Es nood, Jean Baptiste Guy, Vassiana Via, An	1%
6	Internet 18 words crawled on 11-Sep-2017 scholarworks.iupui.edu	1%

[全部](#)[新闻](#)[图片](#)[购物](#)[地图](#)[更多](#)[设置](#)[工具](#)

找到约 69,100 条结果 (用时 0.54 秒)

Sustained Complete Response after Maintenance Therapy with ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3934679/> ▼ [翻译此页](#)作者 : D Callegaro-Filho - 2014 - 被引用次数 : 4 - [相关文章](#)

2014年1月31日 - A 53-year-old woman with stage IB2 **squamous cell carcinoma** of the ... In this **report**, we describe a **case** of **sustained complete response** in a ... A second **study** evaluated **erlotinib** in combination with cisplatin in Epidermal growth factor receptor targeted therapy in stages III and IV **head and neck** cancer.

a phase ii trial of erlotinib in recurrent squamous cell carcinoma of the ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2722934/> ▼ [翻译此页](#)作者 : RJ Schilder - 2009 - 被引用次数 : 92 - [相关文章](#)

Twenty-eight patients with **squamous cell carcinoma** were enrolled onto this trial. ... 11,000 new **cases** of cervical cancer with 3700 deaths estimated for 2007(2). ^a-CR: **complete response**; PR- partial response; PFS- progression-free survival also may be more active than EGFR TKIs in **head and neck** cancer(33-38).

A Phase II Study of Erlotinib and Bevacizumab in Patients with ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2768532/> ▼ [翻译此页](#)作者 : EEW Cohen - 2009 - 被引用次数 : 266 - [相关文章](#)

2010年3月1日 - The observed response rate was 15% with 4 **complete responses** (CR) ... Some patients appear to derive a **sustained** benefit and **complete responses** were associated ... **Squamous cell carcinoma of the head and neck** (squamous cell (23 **cases**)) and diarrhea [any grade (16 **cases**)] with outcomes was ...

Erlotinib and bevacizumab in patients with recurrent ... - ResearchGate

https://www.researchgate.net/.../23989095_Erlotinib_and_bevacizumab_in_... - [翻译此页](#)

[全部](#)[新闻](#)[图片](#)[购物](#)[地图](#)[更多](#)[设置](#)[工具](#)

找到约 72,600 条结果 (用时 0.41 秒)

(PDF) Complete response in gallbladder cancer to erlotinib plus ...

https://www.researchgate.net/.../47509174_Complete_response_in_gallbladd... - 翻译此页

This **case report** demonstrates a patient with stage IV gallbladder cancer who experienced **Erlotinib Response in Head and Neck Squamous Cell Carcinoma**.

Sustained Complete Response after Maintenance Therapy with ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3934679/> ▼ 翻译此页

作者 : D Callegaro-Filho - 2014 - 被引用次数 : 4 - 相关文章

2014年1月31日 - In this **report**, we describe a **case of sustained complete response** in a II trial of **erlotinib** in recurrent **squamous cell carcinoma** of the cervix: a ...

A Phase II Study of Erlotinib and Bevacizumab in Patients with ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2768532/> ▼ 翻译此页

作者 : EEW Cohen - 2009 - 被引用次数 : 266 - 相关文章

Some patients appear to derive a **sustained benefit** and **complete responses** were ... **Squamous cell carcinoma of the head and neck (squamous cell carcinoma of cases)]** and diarrhea [any grade (16 cases)] with outcomes was examined.

Erlotinib and bevacizumab in patients with recurrent or metastatic ...

<https://europepmc.org/abstract/med/19201650> - 翻译此页

作者 : EE Cohen - 2009 - 被引用次数 : 265 - 相关文章

Epidermal growth factor receptor (EGFR) is a validated target in **squamous-cell carcinoma of the head and neck**, but in patients with recurrent or metastatic ...

Head-to-head Phase III trial demonstrates superior progression-free ...

<https://www.boehringer-ingenheim.com/.../head-head-phase-iii-trial-demonst...> ▼ 翻译此页

[全部](#)[新闻](#)[图片](#)[视频](#)[购物](#)[更多](#)[设置](#)[工具](#)

找到约 71,100 条结果 (用时 0.68 秒)

Sustained Complete Response after Maintenance Therapy with ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3934679/> ▼ [翻译此页](#)

作者: D Callegaro-Filho - 2014 - 被引用次数: 4 - [相关文章](#)

2014年1月31日 - A 53-year-old woman with stage IB2 squamous cell carcinoma of the ... In this report, we describe a case of sustained complete response in a ... A second study evaluated erlotinib in combination with cisplatin in Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer.

A Phase II Study of Erlotinib and Bevacizumab in Patients with ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2768532/> ▼ [翻译此页](#)

作者: EEW Cohen - 2009 - 被引用次数: 266 - [相关文章](#)

Some patients appear to derive a sustained benefit and complete responses were ... Squamous cell carcinoma of the head and neck (squamous cell carcinoma of cases)] and diarrhea [any grade (16 cases)] with outcomes was examined.

Tarceva – Oral Cancer News

<https://oralcancernews.org/wp/tag/tarceva/> ▼ [翻译此页](#)

Erlotinib dose doubled for smokers with head/neck cancer ... of erlotinib before definitive surgery for squamous cell carcinoma of the head and neck resulted in favorable responses for the first patients evaluated in a small pilot study. ... the case study of a smoker with a very large oral cavity tumor protruding through his lips.

(PDF) Genomic Correlate of Exceptional Erlotinib Response in Head ...

https://www.researchgate.net/.../276835782_Genomic_Correlate_of_Excepti... - [翻译此页](#)

2018年8月1日 - tients with head and neck squamous cell carcinoma ... Complete responses to EGFR TKIs in solid tumors are ... Report of a Case ... Mechanism of Exceptional Erlotinib Response Brief